Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(05), P. 1525 - 1532
Published: Jan. 1, 2025
Language: Английский
Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(05), P. 1525 - 1532
Published: Jan. 1, 2025
Language: Английский
Clinical & Translational Oncology, Journal Year: 2025, Volume and Issue: unknown
Published: March 6, 2025
Language: Английский
Citations
0Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown
Published: March 11, 2025
Language: Английский
Citations
0Cancers, Journal Year: 2025, Volume and Issue: 17(8), P. 1267 - 1267
Published: April 9, 2025
Background/Objectives: Persistent infection with high-risk (HR) HPV genotypes is the main risk factor for development of cervical cancer. The present analysis provides recent trends on HR-HPV rates and distribution among 3500 Greek women between 2021 2023. Methods: detection HR-HPVs specific identification HPV16 HPV18 were conducted using Roche Cobas 4800 assay. genotyping 12 other was performed through Nested Multiplex PCR methodology (NMPCR). Results: overall rate 8.8% most prevalent genotype being followed by HPV31, HPV66, HPV56, HPV51, HPV58, HPV45, HPV18, HPV68, HPV59, HPV52, HPV35, HPV39, HPV33. Among HR-HPV-positive cases prevalence single, double, triple, quadruple infections 73.9%, 19.9%, 5.5%, 0.7%, respectively. Age-specific showed that higher in age group 31–35 years (25.5%) it estimated multiple occur more often younger women. Notably, varies different groups. It proposed HPV16, HPV66 may show an increased possibility establishing long-term over 36 old. Conclusions: high which are not included prophylactic vaccines underlines significance constant surveillance circulating HPVs population.
Language: Английский
Citations
0Research in Veterinary Science, Journal Year: 2025, Volume and Issue: unknown, P. 105656 - 105656
Published: April 1, 2025
Language: Английский
Citations
0Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(4)
Published: April 1, 2025
Abstract Background High‐risk human papillomavirus (HPV), especially HPV16, is closely correlated with certain cancers. E6 and E7 proteins of HPV16 play critical roles in oncogenesis, making them optimal targets for treating HPV‐associated Here, we engineered an innovative vaccine, Ad‐E6/7‐HR, designed to evoke immune responses through the incorporation self‐assembling heptad‐repeat 1 (HR1) HR2 originated from Severe acute respiratory syndrome coronavirus 2. Methods Ad‐E6/7‐HR was constructed utilising a replication‐defective adenovirus serotype 5 vector evaluated its immunogenicity therapeutic efficacy murine models. We verified antitumour vaccine TC‐1 subcutaneous pulmonary Flow cytometry, enzyme‐linked immunospot assay, immunofluorescence staining were used assess cellular Ad‐E6/7‐HR. Results induced robust responses, significantly increasing antigen‐specific CD8 + T cells. The also enhanced memory T‐cell generation potent cytokine secretion, as exemplified by interferon‐γ tumour necrosis factor‐α. conferred complete protection against growth prophylactic model. In settings, reduced size improved survival. Furthermore, reshaped microenvironment increased recruitment immunosuppressive cells, like myeloid‐derived suppressor cells M2 macrophages, thereby enhancing immunity. Conclusions By targeting leveraging HR1 sequences enhance represented promising candidate preventing Further clinical investigation warranted evaluate potential trials.
Language: Английский
Citations
0Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: April 29, 2025
Language: Английский
Citations
0Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(05), P. 1525 - 1532
Published: Jan. 1, 2025
Language: Английский
Citations
0